<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The aim of this study was to identify novel and reliable serum markers related to the prognosis of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) patients and to assess the association between selected markers and clinical outcome </plain></SENT>
<SENT sid="1" pm="."><plain>We performed experiments using cytokine arrays to investigate the cytokine profiles in serum from stage IV <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients, compared with those of stage I patients </plain></SENT>
<SENT sid="2" pm="."><plain>Serum CXCL10 was measured using an ELISA in 218 CRC patients and 17 <z:mpath ids='MPATH_458'>normal</z:mpath> volunteers to clarify the association of CXCL10 with clinical outcome </plain></SENT>
<SENT sid="3" pm="."><plain>The mean serum CXCL10 concentration in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients was significantly higher compared to that in <z:mpath ids='MPATH_458'>normal</z:mpath> volunteers </plain></SENT>
<SENT sid="4" pm="."><plain>Serum CXCL10 levels increased significantly in accordance with the progression of UICC stage classification </plain></SENT>
<SENT sid="5" pm="."><plain>Serum CXCL10 was significantly associated with high pathological T stage, the presence of vascular invasion and distant <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Elevated serum CXCL10 levels were significantly associated with poor survival in <z:hpo ids='HP_0000001'>all</z:hpo> stages or in stage I-III with curative patients, respectively, and were an independent marker in predicting <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastasis</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Immunohistochemical analysis showed that CXCL10 was expressed in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells at <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumor</z:e> and <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> sites, and in <z:mpath ids='MPATH_458'>normal</z:mpath> liver tissue surrounding <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastatic cancer</z:e> cells </plain></SENT>
<SENT sid="8" pm="."><plain>Comprehensive analysis using cytokine arrays identified the novel serum prognosis marker CXCL10 </plain></SENT>
<SENT sid="9" pm="."><plain>Preoperative high serum levels of CXCL10 were associated with poor prognosis and <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastasis</z:e> in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
</text></document>